Determine the optimal use of the superconductive quantum interference device (squid)/mri in low-field nmr. The technical advantages are a simpler magnet, a convenient, low cost magnet system for use in interventional procedures.
In previous projects, efficient micropropagation, regeneration and transformation procedures have been developed. In this project we intend to commercially micropropagate elite apricot cultivars and regenerate transformed apricot plantlets
Vascular diseases (stroke, myocardial infarction, peripheral vessel occlusion) are still increasing in western countries. To improve the early diagnosis and therapy of this generalised disease, combined analysis needs to be provided
Topical dna (deoxyribose nucleic acid) patch vaccine therapy is a novel investigational medicinal product for the treatment of hiv/aids. We will conduct human trials for proof of concept of the antiviral efficacy on hiv+ drug naive and drug failing patients.
The geometry of airways will be generated by medical image techniques. Numerical models and aerosol measuring systems will be developed to analyse inhaled aerosol deposition. Human and in-vitro experiments will then validate the results.
To develop trace element premixes which comply with food safety and environmental requirements and have a beneficial biological effect. Our task is also to measure and calculate the biologically and economically effective dose for the different animal species.
To develop a novel medical sensor assembly for the in-vivo study of clinically important molecules. The sensor system will be developed to a stage where it is ready to become a commercial product.
Development of kits and protocols for targeted next generation sequencing of 58 genes carrying potential deleterious mutations linked to breast/ovarian cancers and congenital myasthenic syndromes. Target-specific data analysis methods will be developed and validated for specificity and sensitivity.
Doxebo is a liposomal formulation jointly invented by the israeli and hungarian applicants. It reduces the risk of serious, occasionally lethal adverse effect of doxil and other similar nano-drugs. In this application we propose preclinical studies necessary for regulatory approval of doxebo.
The mission of the consortium is to utilize state-of-the-art pharmaceutical approaches and develop tnf-alpha-binding protein-imprinted polymers for the specific elimination of tnf-alpha from the gastrointestinal tract hence improving the therapy of currently untreatable crohn's disease.